Recent clinical trials about SGLT2 inhibitors have shown that flozin therapy, especially with dapagliflozin, in patients with heart failure reduces mortality and hospitalizations [55,75], regardless of the presence of diabetes mellitus [88], GFR rate, or albuminuria. This evidence concerns the gene SLC5A2 and diabetes mellitus.